Immunocore Holdings plc
Develops TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
IMCR | US
Overview
Corporate Details
- ISIN(s):
- US45258D1054
- LEI:
- Country:
- United States of America
- Address:
- 90 PARK DRIVE, OXFORDSHIRE
- Website:
- https://www.immunocore.com/
- Sector:
- Manufacturing
Description
Immunocore Holdings plc is a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies. Its proprietary ImmTAX (Immune mobilizing monoclonal TCRs against X disease) platform is designed to harness the body's immune system. The technology engineers TCRs to recognize and target diseased cells, making them visible for destruction by the immune system, or to suppress the immune system in autoimmune conditions. The company's diverse clinical pipeline targets a broad range of indications, including solid tumors, infectious diseases such as HIV and hepatitis B, and autoimmune disorders. Immunocore developed and commercialized the world's first approved TCR therapy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immunocore Holdings plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunocore Holdings plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunocore Holdings plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
